AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass

Bone

Volumn 47, Issue 2, 2010, Pages 309-319

  Shah, M ^a   Kola, B ^b   Bataveljic, A ^a   Arnett, T R ^c   Viollet, B ^d   Saxon, L ^a   Korbonits, M ^b   Chenu, C ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d INSERM   (France)

Author keywords

AMP kinase; Bone; Energy metabolism; Knockout mice; Metformin; Osteoblasts

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ALKALINE PHOSPHATASE; GHRELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROPRANOLOL; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ENZYME ACTIVATOR; MESSENGER RNA; PROTEIN SUBUNIT; RIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBUNIT; GENE LOCATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; PHENOTYPE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIBIA; TRABECULAR BONE; WESTERN BLOTTING; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; BONE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROSECRETION; ORGAN SIZE; PHYSIOLOGY; PROTEIN SUBUNIT;

ALKALINE PHOSPHATASE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVATORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; METFORMIN; MICE; MICE, KNOCKOUT; NEUROSECRETORY SYSTEMS; ORGAN SIZE; OSTEOBLASTS; OSTEOGENESIS; PHENOTYPE; PROTEIN SUBUNITS; RATS; RIBONUCLEOTIDES; RNA, MESSENGER; TIBIA;

EID: 77955984299     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.04.596     Document Type: Article

References (72)

1. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
2. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
3. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
4. Oei L., Tontonoz P. Fat's loss is bone's gain. J Clin Invest 2004, 113:805-806.
5. Rosen C.J., Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol 2006, 2:35-43.
6. Hardie D.G., Hawley S.A., Scott J.W. AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006, 574:7-15.
7. Kola B., Boscaro M., Rutter G.A., Grossman A.B., Korbonits M. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 2006, 17:205-215.
8. Lage R., Diéguez C., Vidal-Puig A., López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008, 14:539-549.
9. Steinberg G.R., Kemp B.C. AMPK in health and disease. Physiol Rev 2009, 89:1025-1078.
10. Oakhill J.S., Scott J.W., Kemp B.E. Structure and function of AMP-activated protein kinase. Acta Physiol 2009, 196:3-14.
11. Hardie D.G. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004, 117:5479-5487.
12. Bright N.J., Thornton C., Carling D. The regulation of mammalian AMPK-related kinases. Acta Physiol 2009, 196:15-26.
13. Qi J., Gong J., Zhao T., Zhao J., Lam P., Ye J., et al. Downregulation of AMPK-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. EMBO J 2008, 27:1537-1548.
14. Costanzo-Garvey D.L., Pfluger P.T., Dougherty M.K., Stock J.L., Boehm M., Chaika O., et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab 2009, 10:366-378.
15. McBride A., Ghilagaber S., Nikolaev A., Hardie D.G. The glycogen-binding domain on the AMPK β subunit allows the kinase to act as a glycogen sensor. Cell Metab 2009, 9:23-34.
16. McGee S.L., Hargreaves M. AMPK and transcriptional regulation. Front Biosci 2008, 13:3022-3033.
17. Park H., Kaushik V.K., Constant S., Prentki M., Przybytkowski E., Ruderman N.B., et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem 2002, 277:32571-32577.
18. Zheng D., MacLean P.S., Pohnert S.C., Knight J.B., Olson A.L., Winter W.W., et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001, 91:1073-1083.
19. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005, 18:283-293.
20. Reihill J.A., Ewart M.A., Hardie D.G., Salt I.P. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. Biochem Biophys Res Commun 2007, 354:1084-1088.
21. Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007, 282:30107-30119.
22. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G.D., Muller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
23. Andersson U., Filipsson K., Abbott C.R., Wood A., Smith K., Bloom S.R., et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004, 279:12005-12008.
24. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428:569-574.
25. Kola B., Hubina E., Tucci S.A., Kirkham T.C., Garcia E.A., et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005, 280:25196-25201.
26. Dzamko N.L., Steinberg G.R. AMPK-dependent hormonal regulation of whole-body energy metabolism. Acta Physiol 2009, 196:115-127.
27. Kanazawa I., Yamaguchi T., Yano S., Yamauchi M., Yamamoto M., Sugimoto T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol 2007, 8:51-62.
28. Kanazawa I., Yamaguchi T., Yano S., Yamauchi M., Sugimoto T. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP2 expression. Am J Physiol Endocrinol Metab 2009, 296:E139-E146.
29. Kasai T., Bandow K., Susuki H., Chiba N., Kakimoto K., Ohnishi T., et al. Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol 2009, 221:740-749.
30. Hou C.H., Tan T.W., Tang C.H. AMP-activated protein kinase is involved in cox-2 expression in response to ultrasound in cultured osteoblasts. Cell Signal 2008, 20:978-988.
31. Kim J.E., Ahn M.W., Baek S.H., Lee I.K., Kim Y.W., Kim J.Y., et al. AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast. Bone 2008, 43:394-404.
32. Cornish J., Callon K.E., Bava U., Lin C., Naot D., Hill B.L., et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002, 175:405-415.
33. Hamrick M.W., Ferrari S.L. Leptin and the sympathetic connection of fat to bone. Osteoporos Int 2008, 23:870-878.
34. Sato S., Hanada R., Kimura A., Abe T., Matsumoto T., Iwasaki M., et al. Central control of bone remodeling by neuromedin U. Nat Med 2007, 13:1234-1240.
35. Idris A., Van't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005, 11:774-779.
36. Maccarinelli G., Sibilia V., Torsello A., Raimondo F., Pitto M., Giustina A., et al. Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 2005, 184:249-256.
37. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002, 109:915-921.
38. Ahn J.D., Dubern B., Lubrano-Berthelier C., Clement K., Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 2006, 147:3196-3202.
39. Fryer L.G.D., Parbu-Patel A., Carling D. The anti-diabetic drugs Rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002, 277:25226-25232.
40. Lebrasseur N.K., Kelly M., Tsao T.S., Farmer S.R., Saha A.K., Ruderman N.B., et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006, 291:E175-E181.
41. Cortizo A.M., Sedlinski C., Mc Carthy A.D., Blanco A., Schurman L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006, 536:38-46.
42. Kanazawa I., Yamaguchi T., Yano S., Yamauchi M., Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 2008, 375:414-419.
43. Molinuevo M.S., Schurman L., McCarthy A.D., Cortizo A.M., Tolosa M.J., Gangoiti M.V., et al. Effects of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 2010, 25:211-221.
44. Benvenuti S., Cellai I., Luciani P., Deledda C., Baglioni S., Giuliani C., et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007, 30:RC26-RC30.
45. Lazarenko O.P., Rzonca S.O., Hogue W.R., Swain F.L., Suva L.J., Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669-2680.
46. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92:1305-1310.
47. Lowry O.H., Roberts N.R., Wu M.L., Hixon W.S., Crawford E.J. The quantitative histochemistry of brain. III. Enzyme measurements. J Biol Chem 1954, 207:19-37.
48. Utting J.C., Robins S.P., Brandao-Burch A., Orriss I.R., Behar J., Arnett T.R. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 2006, 312:1693-1702.
49. Viollet B., Andreelli F., Jorgensen S.B., Perrin C., Geloen A., Flamez D., et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003, 111:91-98.
50. Jorgensen S.B., Viollet B., Andreelli F., Frosig C., Birk J.B., Schjerling P., et al. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 2004, 279:1070-1079.
51. Marenzana M., De Souza R., Chenu C. Blockade of beta-adrenergic signalling does not influence the bone mechano-adaptive response in mice. Bone 2007, 41:206-215.
52. Confavreux C.B., Levine R.L., Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009, 310:21-29.
53. Hardie D.G. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007, 47:185-210.
54. Zhou G., Sebhat I.K., Zhang B.B. AMPK activators-potential therapeutics for metabolic and other diseases. Acta Physiol 2009, 196:175-190.
55. Van der Velde M., Delhanty P., Van der Eerden B., Van der Lely A., Van Leeuven J. Ghrelin and bone. Vitam Horm 2007, 77:239-258.
56. Thorens B., Larsen P.J. Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. Curr Opin Clin Nutr Metab Care 2004, 7:471-478.
57. Fu L., Isobe K., Zeng Q., Suzukawa K., Takekoshi K., Kawakami Y. Beta-adrenoreceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 and tumor necrosis factor-alpha expression in adipocytes. Eur J Pharmacol 2007, 569:155-162.
58. Motoshima H., Goldstein B., Igata M., Araki E. AMPK and cell proliferation.-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006, 574:63-71.
59. Rattan R., Giri S., Singh A.K., Singh I. 5-aminomidazole-4-carboxamide-1-β-d-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated kinase. J Biol Chem 2005, 280:39582-39593.
60. CipI. J Mol Signal 2008, 3:18-29.
61. Zhen D., Chen Y., Tang X. Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications Jul 21 2009, [Electronic publication ahead of print].
62. Peuler J.D., Phare S.M., Iannucci A.R., Hodorek M.J. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 1996, 9:188-192.
63. Petty R.G., Pearson J.D. The influence of hypoglycemic agents on the growth and metabolism of human endothelial cells. Diabetes Med 1992, 9:30-37.
64. Ma L., Wu X., Ling-Ling E., Wang D.S., Liu H.C. The transmembrane transport of metformin by osteoblasts from rat mandible. Arch Oral Biol 2009, 54:951-962.
65. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
66. Komorava S.V., Ataullakhanov F.I., Globus R.K. Bioenergetics and mitochondrial transmembrane potential during differentiation of cultured osteoblasts. Am J Physiol Cell Physiol 2000, 279:C1220-C1229.
67. Hwang J.T., Park I.J., Shin J.I., Lee Y.K., Lee S.K., Baik H.W., et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 2005, 338:694-699.
68. Daval M., Diot-Dupuy F., Bazin R., Hainault I., Viollet B., Vaulont S., et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem 2005, 280:25250-25257.
69. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
70. Viollet B., Lantier L., Devin-Leclerc J., Hebrard S., Amouyal C., Mounier R., et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci 2009, 14:3380-3400.
71. Viollet B., Andreelli F., Jørgensen S.B., Perrin C., Flamez D., Mu J., et al. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 2003, 31:216-219.
72. Quinn J.M.W., Tam S., Sims N.A., Saleh H., McGregor N.E., Poulton I.J., et al. Germline deletion of AMPK-activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J 2009, 2010(24):275-285.